Stefano Del Prato discusses the advantages of tirzepatide over insulin glargine for people with type 2 diabetes, and how the SURPASS-4 findings fit with those of the rest of the clinical trial program (7:42).
A real-world study shows a reduced risk for heart failure hospitalization, even in people without pre-existing cardiovascular disease, with use of SGLT2 inhibitors versus GLP-1 receptor agonists.
The presence of gestational diabetes mellitus may identify women at an increased risk for experiencing hospitalization for heart failure within the next few years, research suggests.